ProMIS Neurosciences (PMN) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ProMIS Neurosciences (PMN) has outperformed Serina Therapeutics (SER) over the past year, losing 69.9% versus a loss of 71.9%. Over five years, SER leads with a -95.6% price change compared with -98.2% for PMN. Serina Therapeutics is the larger company by market cap ($29.8 million vs $28.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMN | SER |
|---|---|---|
| Share price | $3.16 | $1.12 |
| Market cap | $28.43M | $29.76M |
| 1-day change | -1.56% | -6.67% |
| YTD return | -53.73% | -41.45% |
| 1-year return | -69.90% | -71.93% |
| 5-year return | -98.24% | -95.64% |
| EPS (TTM) | $-6.50 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $130.00K |
| Revenue growth (YoY) | — | +132.14% |
| Net income (latest FY) | $-39.72M | $-19.18M |
| Operating margin | — | -18478.46% |
| Net margin | — | -14755.38% |
| 52-week high | $27.40 | $4.26 |
| 52-week low | $2.78 | $1.06 |
| Distance from 52-week high | -88.47% | -73.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +1248.42% | +748.21% |
| Average volume | 164.88K | 68.98K |
| Shares outstanding | 9.00M | 26.57M |
| Employees | 10 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
PMN vs SER FAQ
Which is bigger, ProMIS Neurosciences or Serina Therapeutics?
Serina Therapeutics (SER) is larger, with a market capitalization of $29.76M compared with $28.43M for ProMIS Neurosciences (PMN).
Which stock has performed better over the past year, PMN or SER?
PMN returned -69.90% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.
Are ProMIS Neurosciences and Serina Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.